Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients

Cancer

Volumn 116, Issue 23, 2010, Pages 5440-5451

  Huang, Xiao Yong ^a   Ke, Ai Wu ^a,b   Shi, Guo Ming ^a   Ding, Zhen Bin ^a   Devbhandari, Ranjan Prasad ^a   Gu, Fang Ming ^a   Li, Quan Lin ^a   Dai, Zhi ^a   Zhou, Jian ^a,b   Fan, Jia ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

biomarker; c Met; CD151; intrahepatic cholangiocarcinoma; prognosis

Indexed keywords

CD151 ANTIGEN; LENTIVIRUS VECTOR; MESSENGER RNA; METHYLNITRONITROSOGUANIDINE; SHORT HAIRPIN RNA; TUMOR MARKER;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRAHEPATIC CHOLANGIOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PHENOTYPE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; TISSUE MICROARRAY;

ANTIGENS, CD; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 78649530456     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25485     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Zhou XD, Tang ZY, Fan J, et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009; 135: 1073-1080.
3. Patel T., Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33: 1353-1357.
4. Hemler ME., Specific tetraspanin functions. J Cell Biol. 2001; 155: 1103-1107.
5. Hemler ME., Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005; 6: 801-811.
6. Zoller M., Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009; 9: 40-55.
7. Yunta M, Lazo PA., Tetraspanin proteins as organisers of membrane microdomains and signalling complexes. Cell Signal. 2003; 15: 559-564.
8. Kazarov AR, Yang X, Stipp CS, et al. An extracellular site on tetraspanin CD151 determines alpha 3 and alpha 6 integrin-dependent cellular morphology. J Cell Biol. 2002; 158: 1299-1309.
9. Ke AW, Shi GM, Zhou J, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology. 2009; 49: 491-503.
10. Zijlstra A, Lewis J, Degryse B, et al. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell. 2008; 13: 221-234.
11. Yang XH, Richardson AL, Torres-Arzayus MI, et al. CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Cancer Res. 2008; 68: 3204-3213.
12. Klosek SK, Nakashiro K, Hara S, et al. CD151 forms a functional complex with c-Met in human salivary gland cancer cells. Biochem Biophys Res Commun. 2005; 336: 408-416.
13. Ishak KG, Anthony PP, Sobin LH., Nonepithelial tumors. In:, Ishak KG, ed. World Health Organization International Classification of Tumors. Berlin, Germany: Springer; 1994: 22-17.
14. Wittekind C., Pitfalls in the classification of liver tumors [in German]. Pathologe. 2006; 27: 289-293.
15. Shi GM, Xu Y, Fan J, et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol. 2008; 134: 1155-1163.
16. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100: 698-711.
17. Iguchi T, Yamashita N, Aishima S, et al. A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model. Oncology. 2009; 76: 293-300.
18. Testa JE, Brooks PC, Lin JM, et al. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res. 1999; 59: 3812-3820.
19. Gesierich S, Paret C, Hildebrand D, et al. Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res. 2005; 11: 2840-2852.
20. Tokuhara T, Hasegawa H, Hattori N, et al. Clinical significance of CD151 gene expression in nonsmall cell lung cancer. Clin Cancer Res. 2001; 7: 4109-4114.
21. Ang J, Lijovic M, Ashman LK, et al. CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator? Cancer Epidemiol Biomarkers Prev. 2004; 13: 1717-1721.
22. Nishiuchi R, Sanzen N, Nada S, et al. Potentiation of the ligand-binding activity of integrin alpha3beta1 via association with tetraspanin CD151. Proc Natl Acad Sci USA. 2005; 102: 1939-1944.
23. Hemler ME., Targeting of tetraspanin proteins-potential benefits and strategies. Nat Rev Drug Discov. 2008; 7: 747-758.
24. Hua LV, Green M, Wong A, et al. Tetraspan protein CD151: a common target of mood stabilizing drugs? Neuropsychopharmacology 2001; 25: 729-736.